Get the Stockscreener App
7.41
3.26%
-0.25
Pre-market:
7.01
-0.40
-5.40%
Alumis Inc stock is traded at $7.41, with a volume of 122.76K.
It is down -3.26% in the last 24 hours and down -15.99% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$7.66
Open:
$7.66
24h Volume:
122.76K
Relative Volume:
1.11
Market Cap:
$403.16M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.01%
1M Performance:
-15.99%
6M Performance:
-40.72%
1Y Performance:
+0.00%
1-Day Range:
$7.24
$7.74
1-Week Range:
$7.24
$7.89
52-Week Range:
$6.75
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.41 | 403.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
How To Trade (ALMS) - Stock Traders Daily
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Where are the Opportunities in (ALMS) - Stock Traders Daily
Barclays PLC Has $230,000 Holdings in Bel Fuse Inc. (NASDAQ:BELFA) - Defense World
Principal Financial Group Inc. Invests $289,000 in iShares MBS ETF (NASDAQ:MBB) - Defense World
Jane Street Group LLC Grows Stock Position in Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) - Defense World
Alumis’ (ALMS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Geode Capital Management LLC Purchases Shares of 305,680 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Barclays PLC Buys Shares of 18,360 Alumis Inc. (NASDAQ:ALMS) - Defense World
UWM Holdings Co. (NYSE:UWMC) Shares Bought by Barclays PLC - Defense World
Alumis (NASDAQ:ALMS) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reaffirms Buy rating on Alumis stock following Bristol-Myer's PsA data - Investing.com
Piedmont Lithium Inc. (NASDAQ:PLL) Given Average Recommendation of “Hold” by Analysts - Defense World
State Street Corp Makes New Investment in Alumis Inc. (NASDAQ:ALMS) - Defense World
State Street Corp Purchases Shares of 81,059 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
hedge funds investors of Alumis Inc. (NASDAQ:ALMS) must be disappointed after last week's 10% drop - Simply Wall St
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Brokerages - Defense World
Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), - Yahoo Finance
Stifel Financial Corp Invests $931,000 in Alumis Inc. (NASDAQ:ALMS) - Defense World
Stifel Financial Corp Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis’ (ALMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
BNP Paribas Financial Markets Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor - Yahoo! Voices
Alumis (NASDAQ:ALMS) Given "Buy" Rating at HC Wainwright - MarketBeat
Alumis reports promising Phase 1 trial results for MS drug - Investing.com
Alumis reports promising Phase 1 trial results for MS drug By Investing.com - Investing.com South Africa
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - The Manila Times
Alumis Reports Breakthrough Clinical Data: TYK2 Drug Shows Strong Brain Penetration in Phase 1 Trial - StockTitan
Charles Schwab Investment Management Inc. Takes $1.16 Million Position in Alumis Inc. (NASDAQ:ALMS) - Defense World
Charles Schwab Investment Management Inc. Invests $1.16 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To Expire on December 25th - Defense World
Alumis Inc.'s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th - MarketBeat
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Pre-market Movers: LOOP, RPTX, CADL, INO, ISPC… - RTTNews
(ALMS) Technical Data - Stock Traders Daily
Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Samsara BioCapital LLC Acquires Shares of 3,266,498 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Quantisnow
How the (ALMS) price action is used to our Advantage - Stock Traders Daily
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Ally Bridge Group NY LLC Cuts Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis: A Best-In-Class TYK2 Inhibitor (NASDAQ:ALMS) - Seeking Alpha
Alumis updates clinical trial dates for lupus study By Investing.com - Investing.com Australia
Alumis updates clinical trial dates for lupus study - Investing.com
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat
HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $26.00 - Defense World
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis Inc Stock (ALMS) Financials Data
There is no financial data for Alumis Inc (ALMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):